Abstract
Introduction
The E3s also contribute to insulin resistance and insulin deficiency by degrading the insulin 124 receptor (IR), the insulin receptor substrate (IRS) and regulating insulin gene transcription.
125
What's more, the E3s are involved in cardiac apoptosis, hypertrophy, and fibrosis, which are 126 the main cardiac structural changes associated with diabetes. These studies suggest that the 127 E3s act as a causative factor of DCM. Up to now, although many molecular mechanisms diabetic patients suffering from heart failure without other comorbidities (82) . Later, these 136 findings were confirmed by large epidemiological studies (23, 37). As diabetes 137 synergistically works with concomitant obesity, hypertension and dyslipidemia, it is difficult 138 to distinguish between a pure diabetic etiology and other cardiovascular risk factors, thus the 139 concept of DCM as an independent disease entity has remained imprecise, and some scholars 140 refute that DCM exists at all (49). However, animal studies increasingly show that diabetes 141 alone could cause cardiac functional and structural changes (22). In vitro cellular studies 142 using high glucose and palmitate to mimic diabetes also provide similar results. These studies 143 strongly support the existence of DCM.
144
It is appreciated now that in diabetic heart, insulin signaling is blunted; cardiomyocytes 145 have to increase fatty acid oxidation to maintain ATP production, which is concomitant with transcription. An early indicator of diabetes-induced changes, extracellular matrix remodeling
153
(also described as collagen accumulation), , helps to explain why diastolic dysfunction is an 154 early sign of DCM and precedes the development of systolic dysfunction (12). As diabetes 155 progresses, these processes are exacerbated, leading to significant apoptosis, fibrosis, and 156 hypertrophy. Once hypertrophy can no longer compensate for cell loss due to apoptosis and 157 infiltration of fibrosis, systolic dysfunction emerges, which marks the transition to the late 158 and irreversible stage of DCM. In the clinic, DCM typically first presents as heart failure with 159 preserved ejection fraction, with features similar to restrictive cardiomyopathy. DCM then 160 evolves into heart failure with reduced ejection fraction similar to dilated cardiomyopathy 161 (19). The prognosis in patients with systolic dysfunction is poor, and is further exacerbated 162 by concomitant diabetes (15).
163
As illustrated in Figure 1 , therefore, the main pathophysiological features of DCM 164 include the shift in metabolic substrates at the early stage, followed by enhanced ROS 165 generation, altered intracellular calcium transport and contractile apparatus, and increased 166 cardiomyocyte apoptosis, and then cardiac myocyte hypertrophy and fibrosis, leading to end-167 stage cardiac diastolic and systolic dysfunction.
168
Understanding how diabetes damages the heart in animals can be translated to develop 169 strategies to guard against clinical heart failure with concomitant diabetes in humans. identified, but almost a dozen types of E2 enzymes and hundreds of E3s have been identified.
192
Considering the E3s have specificity for their substrates, the number of E3s accounts for their 193 multiple and complex functions (98) .
194
To date, the E3s are divided into 3 classes according to structural similarities: the Really
195
Interesting New Gene finger proteins (the RING finger proteins, the most abundant class of Two important issues in diabetes are insulin deficiency and insulin resistance. Table 1 205 lists several E3s known to be involved in diabetes. The E3s contribute to both insulin 206 deficiency and insulin resistance via multiple mechanisms (Figure 2 ).
207
The Krüppel-like protein Gli-similar 3 (Glis3) is a transcription factor that plays a vital 
228
These E3s mediate degradation of IR or IRS, thus directly promoting insulin resistance.
229
In contrast, one member of E3s, Pellino3, protects against high fat diet-induced insulin 
250
In sum, the E3s not only interfere with insulin signaling, but also regulate lipid, glucose 251 and whole body energy metabolism, thus it could be a therapeutic target in diabetes and its 252 cardiovascular complications. 
The roles of E3 ubiquitin ligases in diabetes-induced cardiac remodeling

257
Under diabetic conditions, the heart had to undergo a serial of remodeling both in and Smad3 (R-Smads), whose nuclear translocation can activate transcription of a select set 271 of pro-fibrosis genes, common partner Smad4 and inhibitory Smad6 and Smad7 (I-Smads).
272
The Smad 7 is a key regulator of TGF-β signaling through negative feedback loops (32). It 
280
The Smad ubiquitination regulatory factor 1 (Smurf1) and factor 2 (Smurf2) bind to TGF-β can directly bind to the FoxOs, promoting their ubiquitination and degradation (21, 39, 51).
428
Besides their proteolytic function, some member of E3s also regulate activity of FoxOs via promising strategies to rescue heart in diabetes. Currently, there is no study using inhibitor or 442 activator of the E3s to treat DCM, but several reagents used to rescue the heart from diabetes 443 indeed regulate activities of the E3s.
444
AMPK is an important molecule involved in DCM and its activity is regulated by the suggests that the E3s may be a novel therapeutic target to treat DCM.
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899
Illustrations were made based on the previous works (38, 103, 112). 
901
Propelled by these TFs, the cardiomyocytes gradually undergo hypertrophy, 902 fibrosis and apoptosis, eventually resulting in cardiac systolic and diastolic 903 dysfunction, thereby advancing the development of DCM.
